Sub Heading

Clinical Trials Details

A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

IRB Protocol Number
EZH-302

Clinical Trial Categories

  • Lymphomas
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: 18 years or older who have been previously treated with at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy for follicular lymphoma and have documented relapsed, refractory, or progressive disease.

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.